Adaptive COVID-19 Treatment Trial (ACTT)

- ACTT-1: NIH clinical trial of antiviral remdesivir to treat COVID-19
  - Preliminary report published online in New England Journal of Medicine (5/22/2020)
- ACTT-2: NIH clinical trial testing remdesivir plus anti-inflammatory baricitinib
  - Fully enrolled (n=1,034) as of 6/30/2020
- ACTT-3: NIH clinical trial testing remdesivir plus immunomodulator interferon beta-1a
  - NIAID announced study launch on 8/5/2020

Patients who received remdesivir had a 32% faster time to recovery than those who received placebo (p<0.001)
Results also suggested a survival benefit
N=1,063 patients from 10 countries (U.S., Europe, Asia)
Phase 3 Clinical Trial of Investigational Vaccine for COVID-19 Begins

Experimental COVID-19 vaccine mRNA-1273 safe, immunogenic in healthy volunteers ages 18-55 years

N=45

Clinical Trials of Monoclonal Antibodies to Prevent COVID-19 Now Enrolling

NIH Launches Clinical Trials Network to Test COVID-19 Vaccines and Other Prevention Tools

COVID-19: Pediatric Research

Study to determine the incidence of novel coronavirus infection in U.S. children begins

- NIH-funded study will ascertain percentage of infected children who develop COVID-19
- The study, called Human Epidemiology and Response to SARS-CoV-2 (HEROS), will help determine what percentage of children infected with SARS-CoV-2 develop symptoms of the disease.

COVID-19: Pediatric Research

NIH-funded project seeks to identify children at risk for MIS-C

- MIS-C is thought to be a severe complication of COVID-19
- Up to $20 million will be awarded to successful research proposals over four years

NIH-funded study to evaluate drugs prescribed to children with COVID-19

- Researchers will assess dosage, metabolism and other properties not yet determined in children
- Conducted in approximately 40 sites of the NICHD-funded Pediatric Trials Network
- Many study sites are located near diverse communities, given reports that COVID-19 disproportionately affects racial and ethnic minorities across all ages

Q&A with Dr. Collins and Dr. Fauci on COVID-19 Vaccines

Clinical Trials of Monoclonal Antibodies to Prevent COVID-19 Now Enrolling

Phase 3 Trials Conducted in the NIAID COVID-19 Prevention Network

Two Phase 3, randomized, placebo-controlled, double-blind clinical trials testing whether experimental monoclonal antibodies (mAbs), can prevent infection in individuals at high risk for COVID-19, will be conducted at clinical sites in the United States. The trials are called mAb Study to Prevent COVID-19 (mAbPCOV) and Neutralizing Antibody Study to Prevent COVID-19 (NAbPCOV).
COVID-19 and Pregnancy

NIH-funded study to investigate pregnancy outcomes resulting from COVID-19 pandemic

- Multipronged study to understand the effects of the COVID-19 pandemic during and after pregnancy.
- The study will be conducted by researchers in the Maternal-Fetal Medicine Units (MFMU) Network funded by NIH's Eunice Kennedy Shriver NICHD.

Vaccine to Protect Broadly Against Mosquito-Borne Diseases Appears Safe

THE LANCET
Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial

[Image of mosquito]